Publications by authors named "Ivan Gergel"
Context: Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed.
Objective: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil.
Article Synopsis
- Escitalopram, a specific isomer of citalopram, shows significant effectiveness in reducing panic attacks among outpatients diagnosed with panic disorder in a controlled clinical trial.
- The study involved 366 participants who were treated with either escitalopram, citalopram, or placebo over 10 weeks, with outcomes measured primarily by the frequency of panic attacks.
- Results indicated that escitalopram significantly improved panic attack frequency compared to placebo, and it was found to be safe and well-tolerated, with similar rates of adverse effects across treatment groups.
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
J Clin Psychiatry
April 2002
Background: Escitalopram is the single isomer responsible for the serotonin reuptake inhibition produced by the racemic antidepressant citalopram. The present randomized, double-blind, placebo-controlled, fixed-dose multicenter trial was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of major depressive disorder.
Method: Outpatients with an ongoing DSM-IV major depressive episode (N = 491) were randomly assigned to placebo, escitalopram, 10 mg/day, escitalopram, 20 mg/day, or citalopram, 40 mg/day, and entered an 8-week double-blind treatment period following a 1-week single-blind placebo lead-in.